Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 14,000 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $255,360.00.

Kiniksa Pharmaceuticals Stock Down 2.1 %

Kiniksa Pharmaceuticals stock traded down $0.42 during trading hours on Wednesday, reaching $19.28. 243,957 shares of the company’s stock were exchanged, compared to its average volume of 589,623. The firm has a market capitalization of $1.39 billion, a PE ratio of -137.70 and a beta of 0.32. The firm’s 50 day simple moving average is $19.92 and its 200 day simple moving average is $22.99. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15.

Analysts Set New Price Targets

A number of research firms recently weighed in on KNSA. JPMorgan Chase & Co. increased their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Finally, Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $36.60.

Institutional Trading of Kiniksa Pharmaceuticals

Several large investors have recently made changes to their positions in the company. CWM LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares in the last quarter. nVerses Capital LLC bought a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $80,000. Hennion & Walsh Asset Management Inc. raised its holdings in Kiniksa Pharmaceuticals by 7.6% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 195,852 shares of the company’s stock worth $4,894,000 after buying an additional 13,886 shares during the last quarter. Semanteon Capital Management LP bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at $551,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after buying an additional 3,076 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.